See more : Aedifica SA (AEDFF) Income Statement Analysis – Financial Results
Complete financial analysis of Lexicon Pharmaceuticals, Inc. (LXRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Lexicon Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Yakiniku Sakai Holdings Inc. (2694.T) Income Statement Analysis – Financial Results
- Telecom Italia S.p.A. (TIT.MI) Income Statement Analysis – Financial Results
- Jaxon Mining Inc. (JXMNF) Income Statement Analysis – Financial Results
- PT Estika Tata Tiara Tbk (BEEF.JK) Income Statement Analysis – Financial Results
- Fujian Septwolves Industry Co., Ltd. (002029.SZ) Income Statement Analysis – Financial Results
Lexicon Pharmaceuticals, Inc. (LXRX)
About Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.20M | 139.00K | 298.00K | 24.00M | 322.07M | 63.21M | 90.34M | 83.34M | 130.01M | 22.85M | 2.22M | 1.09M | 1.85M | 4.91M | 10.70M | 32.32M | 50.12M | 72.80M | 75.68M | 61.74M | 42.84M | 35.20M | 305.58M | 14.46M | 4.70M |
| Cost of Revenue | 85.00K | 427.00K | 55.05M | 1.93M | 3.23M | 2.49M | 1.90M | 163.97M | 95.19M | 89.28M | 89.68M | 82.57M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -2.62M | -2.00M |
| Gross Profit | 1.12M | -288.00K | -54.75M | 22.07M | 318.84M | 60.72M | 88.44M | -80.64M | 34.83M | -66.43M | -87.46M | -81.49M | 1.85M | 4.91M | 10.70M | 32.32M | 50.12M | 72.80M | 75.68M | 61.74M | 42.84M | 35.20M | 305.58M | 17.08M | 6.70M |
| Gross Profit Ratio | 92.94% | -207.19% | -18,371.81% | 91.96% | 99.00% | 96.06% | 97.90% | -96.76% | 26.79% | -290.65% | -3,936.09% | -7,482.55% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 118.13% | 142.55% |
| Research & Development | 58.89M | 52.82M | 55.05M | 153.62M | 91.92M | 100.24M | 156.81M | 178.15M | 95.19M | 89.28M | 89.68M | 82.57M | 91.83M | 75.35M | 81.24M | 108.58M | 104.33M | 106.70M | 93.63M | 90.59M | 82.20M | 74.86M | 53.36M | 31.65M | 14.60M |
| General & Administrative | 0.00 | 48.08M | 0.00 | 0.00 | 0.00 | 63.75M | 66.20M | 43.04M | 23.84M | 19.41M | 17.12M | 17.04M | 17.35M | 22.57M | 19.42M | 20.28M | 20.74M | 21.33M | 0.00 | 0.00 | 0.00 | 0.00 | 20.86M | 18.29M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 113.98M | 48.08M | 32.34M | 47.23M | 56.84M | 63.75M | 66.20M | 43.04M | 23.84M | 19.41M | 17.12M | 17.04M | 17.35M | 22.57M | 19.42M | 20.28M | 20.74M | 21.33M | 18.17M | 18.61M | 23.23M | 23.23M | 20.86M | 18.29M | 2.90M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 1.60M | 28.64M | 0.00 | 1.95M | 2.29M | 572.00K | 2.26M | 59.00K | 105.00K | 24.12M | 2.71M | 0.00 | 20.28M | 20.74M | 21.33M | 18.17M | 18.61M | 23.23M | 23.23M | 275.00M | 2.62M | 4.90M |
| Operating Expenses | 172.87M | 100.90M | 87.39M | 200.85M | 148.76M | 164.00M | 223.02M | 221.20M | 119.02M | 108.69M | 106.80M | 99.62M | 115.94M | 100.63M | 100.66M | 128.86M | 125.07M | 128.03M | 111.80M | 109.19M | 105.43M | 98.09M | 349.22M | 52.56M | 19.50M |
| Cost & Expenses | 172.95M | 100.90M | 87.39M | 202.78M | 151.99M | 166.49M | 224.92M | 221.20M | 119.02M | 108.69M | 106.80M | 99.62M | 115.94M | 100.63M | 100.66M | 128.86M | 125.07M | 128.03M | 111.80M | 109.19M | 105.43M | 98.09M | 349.22M | 49.94M | 17.50M |
| Interest Income | 7.73M | 1.60M | 134.00K | 2.77M | 3.35M | 3.51M | 1.95M | 2.29M | 572.00K | 2.26M | 157.00K | 213.00K | 255.00K | 519.00K | 880.00K | 5.76M | 7.29M | 3.65M | 2.65M | 1.64M | 1.80M | 3.23M | 8.78M | 9.90M | 0.00 |
| Interest Expense | 13.10M | 2.78M | 802.00K | 14.54M | 20.68M | 20.78M | 6.98M | 6.57M | 6.72M | 2.25M | 1.97M | 2.11M | 2.53M | 2.72M | 2.97M | 2.69M | 2.77M | 3.25M | 3.28M | 2.66M | 325.00K | 7.00K | 314.00K | 422.04K | 0.00 |
| Depreciation & Amortization | 554.00K | 427.00K | 292.00K | 2.93M | 3.65M | 3.68M | 3.40M | 2.06M | 727.00K | 1.93M | 2.86M | 4.19M | 4.89M | 5.39M | 6.16M | 10.07M | 10.42M | 11.20M | 11.64M | 12.87M | 21.53M | 20.58M | 16.55M | 2.62M | 2.00M |
| EBITDA | -163.46M | -98.74M | -86.66M | -41.10M | 173.74M | -96.09M | -125.27M | -125.82M | 11.72M | -96.18M | -99.29M | -103.91M | -108.80M | -93.69M | -84.29M | -86.26M | -64.53M | -39.98M | -24.48M | -34.58M | -41.06M | -42.31M | -27.09M | -32.86M | -10.80M |
| EBITDA Ratio | -13,576.74% | -71,341.01% | -29,179.87% | -733.56% | 53.85% | -157.84% | -146.82% | -162.67% | 8.89% | -365.72% | -4,696.89% | -9,018.37% | -6,156.84% | -1,939.67% | -832.49% | -256.94% | -127.18% | -61.03% | -33.09% | -58.12% | -95.86% | -120.21% | -8.86% | -227.24% | -229.79% |
| Operating Income | -171.75M | -100.76M | -87.09M | -178.79M | 141.45M | -103.28M | -136.68M | -137.16M | 1.47M | -100.37M | -102.37M | -108.42M | -114.10M | -95.72M | -89.96M | -96.54M | -74.95M | -55.23M | -36.12M | -47.45M | -62.59M | -62.89M | -43.64M | -35.48M | -12.80M |
| Operating Income Ratio | -14,264.95% | -72,489.21% | -29,224.83% | -745.09% | 43.92% | -163.39% | -151.30% | -164.58% | 1.13% | -439.16% | -4,607.16% | -9,955.46% | -6,170.63% | -1,950.24% | -840.71% | -298.68% | -149.56% | -75.87% | -47.73% | -76.86% | -146.12% | -178.67% | -14.28% | -245.37% | -272.34% |
| Total Other Income/Expenses | -5.37M | -1.18M | -668.00K | -10.77M | -17.33M | -17.27M | -5.03M | -4.27M | -6.15M | 2.00K | -1.76M | -1.80M | -2.12M | -6.08M | -3.46M | -349.00K | 3.72M | 801.00K | -77.00K | 282.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -177.12M | -101.94M | -87.76M | -58.57M | 124.12M | -120.55M | -141.71M | -141.43M | -4.68M | -100.36M | -104.13M | -110.21M | -116.22M | -101.80M | -93.42M | -96.88M | -71.23M | 54.43M | 39.20M | -46.15M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -14,710.88% | -73,341.01% | -29,448.99% | -244.11% | 38.54% | -190.71% | -156.87% | -169.71% | -3.60% | -439.15% | -4,686.14% | -10,120.39% | -6,285.29% | -2,074.19% | -873.07% | -299.76% | -142.13% | 74.77% | 51.79% | -74.75% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 1.18M | 510.00K | 11.61M | -6.01M | 3.51M | -12.66M | 4.51M | 6.00M | -70.00K | -833.00K | -1.97M | -2.36M | -26.00K | -102.00K | -19.68M | -16.16M | -119.00K | 119.00K | -282.00K | 1.61M | -3.22M | -8.47M | -9.48M | -300.00K |
| Net Income | -177.12M | -103.13M | -88.27M | -70.18M | 130.13M | -120.55M | -129.05M | -141.43M | -4.68M | -100.29M | -104.13M | -110.21M | -116.22M | -101.78M | -82.78M | -76.86M | -58.79M | -54.31M | -36.32M | -47.17M | -64.20M | -59.67M | -35.17M | -25.99M | -12.50M |
| Net Income Ratio | -14,710.88% | -74,192.81% | -29,620.13% | -292.49% | 40.40% | -190.71% | -142.86% | -169.71% | -3.60% | -438.85% | -4,686.14% | -10,120.39% | -6,285.29% | -2,073.66% | -773.64% | -237.80% | -117.31% | -74.61% | -47.98% | -76.40% | -149.86% | -169.52% | -11.51% | -179.78% | -265.96% |
| EPS | -0.80 | -0.62 | -0.61 | -0.63 | 1.23 | -1.14 | -1.23 | -1.36 | -0.05 | -1.31 | -1.42 | -1.58 | -2.39 | -2.35 | -3.98 | -3.93 | -4.12 | -5.68 | -3.97 | -5.21 | -7.91 | -7.99 | -4.90 | -4.37 | -3.57 |
| EPS Diluted | -0.80 | -0.62 | -0.61 | -0.63 | 1.11 | -1.14 | -1.23 | -1.36 | -0.05 | -1.31 | -1.42 | -1.58 | -2.39 | -2.35 | -3.98 | -3.93 | -4.12 | -5.68 | -3.97 | -5.21 | -7.91 | -7.99 | -4.90 | -4.37 | -3.57 |
| Weighted Avg Shares Out | 221.13M | 165.73M | 145.65M | 110.84M | 106.22M | 105.74M | 105.12M | 103.86M | 103.59M | 76.35M | 73.30M | 69.96M | 48.68M | 43.26M | 20.78M | 19.54M | 14.26M | 9.55M | 9.14M | 9.05M | 8.12M | 7.47M | 7.17M | 5.95M | 3.50M |
| Weighted Avg Shares Out (Dil) | 221.13M | 165.73M | 145.65M | 110.84M | 116.75M | 105.83M | 105.24M | 103.86M | 103.59M | 76.35M | 73.30M | 69.96M | 48.68M | 43.26M | 20.78M | 19.54M | 14.26M | 9.55M | 9.14M | 9.05M | 8.12M | 7.47M | 7.17M | 5.95M | 3.50M |
Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
Strong Interest in Trial Participation Resulted in Enrollment Exceeding Target by 20 Percent and Completion Ahead of Schedule
Lexicon Pharmaceuticals to Participate in December Investor Conferences
THE WOODLANDS, Texas, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that company management, including Mike Exton, Lexicon's chief executive officer and director, will present at two upcoming investor conferences in December.
Lexicon Pharmaceuticals to cut workforce by 60% to focus on drug development
Lexicon Pharmaceuticals said on Friday it would reduce its workforce by about 60%, effective Dec. 31, to eliminate commercial activities and focus on drug development.
Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA
Implementing Strategic Restructuring to Eliminate Commercial Organization and Rationalize Operations Across All Functions
Lexicon Appoints Ivan H. Cheung to Board of Directors
THE WOODLANDS, Texas, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Ivan H. Cheung has been elected to its Board of Directors.
Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2024 Earnings Call Transcript
Start Time: 17:00 January 1, 0000 5:55 PM ET Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX ) Q3 2024 Earnings Call November 12, 2024, 17:00 PM ET Company Participants Mike Exton - CEO and Director Tom Garner - SVP and Chief Commercial Officer...
Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Lags Revenue Estimates
Lexicon Pharmaceuticals (LXRX) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.21 per share a year ago.
Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
Announced Exclusive Licensing Agreement with Viatris for Sotagliflozin in all Markets Outside of the U.S. and Europe
Lexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare Conference
THE WOODLANDS, Texas, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Jefferies London Global Healthcare Conference. Lexicon management including Mike Exton, Lexicon's chief executive officer and director will participate in a...
Published Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People With Type 1 Diabetes and Chronic Kidney Disease
People with T1D and CKD treated with sotagliflozin and insulin had similar lowering effects on glycated hemoglobin (HbA1c), the primary endpoint, as people with T1D who do not have CKD
Source: https://incomestatements.info
Category: Stock Reports